/LO-021 Interim safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; anti-BAFF-R mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus (SLE)

Citation Map

Citing

Cited By

The articles shown here are a subset.See the full list of articles below.

Citing (0)

Sort By:

Data not found

Cited By (0)

Sort By: